Pulse Brain · Growing Health Evidence Index
Tier 4 — Narrative / commentaryIndustry / policy report

Wegovy (2023)

Wegovy

2023

All evidence

Summary

Source report: The GLP-1 Revolution_briefing_v4.pdf File: The GLP-1 Revolution_briefing_v4.pdf Ref#: PCC ref author-year:Wegovy (2023) Original: … ent on NHS were approved in the UK in 2020 (Saxenda), followed by Wegovy (2023) and Mounjaro (2024) – Saxenda was approved for private use in 2017. Sources: IQVIA (2025), NHSBSA (2024), Masson et a …

Outcomes reported

Source report: The GLP-1 Revolution_briefing_v4.pdf File: The GLP-1 Revolution_briefing_v4.pdf Ref#: PCC ref author-year:Wegovy (2023) Original: … ent on NHS were approved in the UK in 2020 (Saxenda), followed by Wegovy (2023) and Mounjaro (2024) – Saxenda was approved for private use in 2017. Sources: IQVIA (2025), NHSBSA (2024), Masson et a …

Theme
Farming systems, soils & land use
Subject
Other / interdisciplinary
Study type
Policy
Study design
Industry report
Source type
Industry/policy report
Status
Published
Geography
United Kingdom
System type
Other
Catalogue ID
IRmoskigyj-107b56
Pulse AI · ask about this record

Dig deeper with Pulse AI.

Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.

What does the evidence say about Other / interdisciplinary?→Tell me more about: Wegovy (2023)→How does this finding apply in a UK context?→What are the most cited records on this topic?→

Related evidence